These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 18256927)

  • 1. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
    Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of RUNX3 inactivation in columnar cell lesions of breast.
    Subramaniam MM; Chan JY; Omar MF; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Histopathology; 2010 Oct; 57(4):555-63. PubMed ID: 20955380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis.
    Subramaniam MM; Chan JY; Soong R; Ito K; Yeoh KG; Wong R; Guenther T; Will O; Chen CL; Kumarasinghe MP; Ito Y; Salto-Tellez M
    Am J Gastroenterol; 2009 Feb; 104(2):426-36. PubMed ID: 19174785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
    Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
    Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic pathways in the evolution of breast ductal carcinoma in situ.
    Farabegoli F; Champeme MH; Bieche I; Santini D; Ceccarelli C; Derenzini M; Lidereau R
    J Pathol; 2002 Mar; 196(3):280-6. PubMed ID: 11857490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
    Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
    Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
    Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
    Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3.
    Tan SH; Ida H; Lau QC; Goh BC; Chieng WS; Loh M; Ito Y
    Oncol Rep; 2007 Nov; 18(5):1225-30. PubMed ID: 17914577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
    Ku JL; Kang SB; Shin YK; Kang HC; Hong SH; Kim IJ; Shin JH; Han IO; Park JG
    Oncogene; 2004 Sep; 23(40):6736-42. PubMed ID: 15273736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization.
    Kuukasjärvi T; Tanner M; Pennanen S; Karhu R; Kallioniemi OP; Isola J
    Am J Pathol; 1997 Apr; 150(4):1465-71. PubMed ID: 9095001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
    Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
    J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Promoter methylation and expression of Runx3 gene in gastric cancer].
    Li LY; Li JK; Shen Y; Yu L; Zhang JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):379-82. PubMed ID: 18636364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.